Singer Capital Markets lead Renalytix’s IPO and raise a further £36 million in 10 months
Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs.
Having incubated out of another one of Singer Capital Markets’ clients, EKF Diagnostics Holdings plc, Renalytix built KidneyIntelX as a platform solution that uses predictive blood-based biomarkers and can analyse continuously further anonymised information from electronic health records, and other genomic data, and integrate with the care management pathways of healthcare systems such as partner and investor, Mount Sinai.
Our work with Renalytix, raising £36 million in 10 months
Secured cornerstone investors, facilitating a larger free float and walking up valuation between the middle and top of the range
Oversubscribed fundraise despite a deteriorating / challenging market , raising £22 million on admission.
The IPO was followed by a secondary Placing in July 2019 raising £14 million.
The IPO on AIM won the prestigious ‘Transaction of the Year’ Award at the AIM Awards Dinner in 2019.
"We are pleased to have chosen Singer Capital Markets to work on these transactions, to help drive the IPO processes, to champion their growth stories and support their journeys as quoted companies. It’s a strong and well-balanced approach – from research, sales and trading and the corporate side – with every part of the team taking the trouble to understand the growth drivers of a proposition and promote its success."
Non-Executive Chairman of Renalytix